Altesa BioSciences, Inc.
🇺🇸United States
Clinical Trials
3
Active:1
Completed:2
Trial Phases
2 Phases
Phase 1:2
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (66.7%)Phase 2
1 (33.3%)A Study to Evaluate Metabolism, Excretion, and Mass Balance of [14C]Vapendavir
- First Posted Date
- 2025-02-19
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Altesa Biosciences, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT06834295
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, UK, United Kingdom
RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection
Phase 2
Active, not recruiting
- Conditions
- RhinovirusVirus Infection, RNAEnterovirus InfectionsRespiratory Tract DiseasesUpper Respiratory DiseaseUpper Respiratory DisorderInfections, RespiratoryCopdCOPD Exacerbation AcuteRhinovirus Infection
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-11-29
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Altesa Biosciences, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT06149494
- Locations
- 🇬🇧
St. Mary's Hospital - Imperial College Respiratory Research Unit (ICRRU), London, United Kingdom
Phase 1 Study Into Pharmacokinetics and Food Effect of Vapendavir in Healthy Participants and Participants With COPD
Phase 1
Completed
- Conditions
- Lower Respiratory DiseasePulmonary DiseaseHealthyRespiratory DiseaseCOPD
- Interventions
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Altesa Biosciences, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT05962645
- Locations
- 🇺🇸
Syneos Health Miami, Miami, Florida, United States
News
No news found